Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
56
resultados
Última actualización
21/06/2025 [08:38:00]
Resultados 25 a 50 de 56
Resumen de: AU2023329330A1
Provided herein are antibodies, or fragments thereof, that specifically bind to a microtubule-binding region (MTBR) of tau, and uses thereof. Further provided are methods of detecting species of MTBR in blood or cerebral spinal fluid, and the use of such detection for diagnosing, prognosing, or staging pathological features and/or clinical symptoms of tauopathies, and to choose treatments appropriate for a given disease stage.
Resumen de: US2024141033A1
The present invention relates to IL-34 antibodies, compositions comprising the same, and methods of using the antibodies and or compositions thereof for treating immune-mediated diseases such as neurodegenerative diseases, for example Alzheimer's Disease or a tauopathy disease.
Resumen de: US2025164471A1
The present disclosure provides a system comprising a communication interface and computer for assigning a label to the biomolecule fingerprint, wherein the label corresponds to a biological state. The present disclosure also provides a sensor arrays for detecting biomolecules and methods of use. In some embodiments, the sensor arrays are capable of determining a disease state in a subject.
Resumen de: WO2025102250A1
A method, system, composition and kit for diagnosis and differential diagnosis of Alzheimer's disease (AD) based on human brain hippocampus spatial transcriptomics. The present invention achieves rapid and efficient early diagnosis and differential diagnosis of AD cognitive disorder by means of one or more of CCK, Neurogranin and PMP2 carried in plasma extracellular vesicles (EVs), thereby achieving high-sensitivity and high-throughput detection of nervous system-derived EVs in peripheral blood, having the advantages of rapidness and low cost, and providing a new technical means and method for clinical application of AD cognitive disorder and large-scale screening-related accurate diagnosis work.
Resumen de: US2025163372A1
A method of inhibiting phosphorylation of the tau protein and/or a TLR4-mediated immune response is disclosed. The method contemplates administering to cells in recognized need thereof such as cells of the central nervous system an effective amount of a of a compound or a pharmaceutically acceptable salt thereof that binds to a pentapeptide of filamin A (FLNA) of SEQ ID NO: 1, and contains at least four of the six pharmacophores of FIGS. 35-40.
Resumen de: US2025163135A1
Disclosed herein are method of diagnosing, selecting, monitoring, and treating subjects with Alzheimer's disease (AD) or suspected of having AD or another disorder associated with amyloid accumulation in the brain.
Resumen de: AU2023308198A1
The present disclosure includes biomarkers, methods, devices, reagents, systems, and kits for the evaluation of risk of dementia in a middle-aged individual within a specified timeframe, for example 5, 10, 15 and/or 20 years. In one aspect, the disclosure provides biomarkers that can be used alone or in various combinations to evaluate risk of dementia within 5, 10, 15 and/or 20 years. In another aspect, methods are provided for evaluating risk of dementia within 5, 10, 15 and/or 20 years in a middle-aged individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 6.
Resumen de: AU2023347307A1
The disclosure relates to lemborexant, a dual orexin receptor antagonist, and compositions and methods for use in treatment of Alzheimer's disease (AD), e.g., in a subject who has AD or who is at risk for developing AD.
Resumen de: WO2025099460A1
The invention relates to calibration standards for use in a single-molecular detection methods, in particular to quantify protein complexes in a sample.
Resumen de: WO2025099457A2
The invention relates to methods of analysing one or more protein complexes in body fluid samples using ultra-sensitive techniques such as single molecule pulldown. The methods find particular use in detecting protein complex biomarkers for the detection or diagnosis of neurodegenerative disorders. The invention also relates to novel combination biomarkers.
Resumen de: WO2025099458A1
The invention relates to methods of determining whether a subject has, or is at risk of developing, a neurodegenerative disorder using ultra-sensitive techniques, in particular a single-molecular array detection method.
Resumen de: AU2023371615A1
Provided herein are biomarkers present in cell-free DNA (cfDNA) for the early detection of pre-clinical Alzheimer's Disease (AD), mild cognitive impairment (MCI), or AD in a subject. The detection of such biomarkers in a subject may be used to inform methods of treating a subject with a therapy (e.g., a drug or biologic) for pre-clinical Alzheimer's Disease (AD), mild cognitive impairment (MCI), or AD. The biomarkers disclosed herein may also be used in methods to monitor the progression of pre-clinical AD, MCI, or AD.
Resumen de: KR20250064344A
본 발명은 알츠하이머병 동물 모델에서 안구 내 알츠하이머 치매 병리 물질의 침착을 평가하는 방법에 관한 것으로, 본 발명의 방법에 따르면, 알츠하이머병 동물 모델의 안구 내 병리 물질(β-아밀로이드 플라크)의 발현을 평가할 수 있는 바, 관련 용도로 유용하게 사용될 수 있다.
Resumen de: WO2025095508A1
The present invention relates to a biohybrid robot including an eye/brain organoid, a motor nerve spheroid, and a muscle bundle, and a manufacturing method therefor. The universal biohybrid robot according to the present invention can generate movement of muscle cells by an electrophysiological signal generated in the eye/brain organoid like a human motor system by using light stimulation and a neurotransmitter. It is expected that the present invention can be used in a disease model simulating a signal transmission system of the human body by combining various neurodegenerative diseases, such as Parkinson and Alzheimer's disease models, and eye tumor models in the future, and can be used to manufacture a drug screening platform that leverages the movement of biohybrid robots composed of living tissues.
Resumen de: WO2025097123A1
Aspects of the invention are drawn to methods for identifying or treating Alzheimer's Disease and/or Alzheimer's Disease and Related Dementias (AD/ADRD) in a subject. Further aspects of the invention are drawn to methods for screening the presence of an Alzheimer's Disease and/or Alzheimer's Disease and Related Dementias (AD/ADRD) signature.
Resumen de: WO2025096789A1
A method of assaying for activity of a protease enzyme corresponding to a disease in a subject includes selectively capturing an extracellular vesicle (EV) from a sample from the subject; contacting the EV after the capturing with a probe molecule, the probe molecule including a peptide, a fluorescent moiety on a first end of the peptide and a quenching moiety on a second end of the peptide to provide a Fluorescence Resonance Energy Transfer (FRET) pair separated by the peptide, the peptide containing a cleavage sequence for the protease enzyme; and measuring a fluorescence of at least the fluorescent moiety after the contacting to indicate a presence or absence of the occurrence of cleavage of the peptide by the protease enzyme.
Resumen de: US2025147049A1
The present disclosure provides methods to quantify and analyze various CSF Tau species and the use thereof to measure pathological features and/or clinical symptoms of tauopathies, including determining the amount of time to dementia due to Alzheimer's disease, determining the time from dementia onset, staging Alzheimer's disease, guiding treatment decisions, and evaluate the clinical efficacy of certain therapeutic interventions.
Resumen de: WO2025093893A1
The present invention relates to methods of measuring the presence and/or levels of a combination of five biomarkers in a sample, said biomarkers being neurofilament light (NfL) polypeptide, glial fibrillary acidic protein (GFAP), β-Amyloid 1-42 (Aβ1-42), β-Amyloid 1-40 (Aβ1-40), and phosphorylated Tau (p-Tau181, pTau-231 and/or p-Tau217). The methods can be used to predict the subject's risk or likelihood of having and/or developing Alzheimer's disease, thus also provided is a method of predicting a subject's risk or likelihood of having and/or developing Alzheimer's disease, said method comprising measuring the presence of and/or the levels of the combination of five biomarkers. Further provided is a method of prognosing or diagnosing Alzheimer's disease in a subject comprising the methods of measuring the presence of and/or the levels of the combination of five biomarkers, and a method of treating Alzheimer's disease comprising predicting a subject's risk or likelihood of developing or having Alzheimer's disease using the methods of measuring the presence and/or levels of the combination of five biomarkers and administering a treatment if the risk or likelihood exceeds a threshold value.
Resumen de: US2025147041A1
Methods for the detection or quantitation of amyloid beta include detecting amyloid beta or fragments thereof by mass spectrometry. The methods may also include determining the ratio of amyloid beta 42 (Aβ42) to amyloid beta 40 (Aβ40). Such methods may include the diagnosis or prognosis of Alzheimer's disease or dementia.
Resumen de: US2025145722A1
Disclosed herein are antibodies and compositions used for binding to Gal3. Some embodiments allow for disrupting interactions between Galectin-3 (Gal3) and cell surface markers and/or proteins associated with neurological diseases and/or proteopathies, such as Alzheimer's disease. Additionally, disclosed herein are methods of treatment and uses of the antibodies or binding fragments thereof for the treatment of fibrosis, liver fibrosis, kidney fibrosis, cardiac fibrosis, pulmonary fibrosis, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, sepsis, atopic dermatitis, psoriasis, cancer, brain cancer, breast cancer, colorectal cancer, kidney cancer, liver cancer, lung cancer, pancreatic cancer, bladder cancer, stomach cancer, hematological malignancy, neurological diseases and/or proteopathies. Furthermore, some embodiments provided herein can cross the blood-brain barrier and can be conjugated or otherwise associated with one or more payloads for the treatment of a neurological disease.
Resumen de: WO2025094139A1
This application is directed to detecting presence or quantity of at least two different molecules. A sensor includes a plurality of chambers, a nanowell array electrode, and a circuit board platform. The sensor separates, cleaves, filters, and detects the at least two different molecules selected from the group consisting of Aβ peptides and tau-protein from a sample in the plurality of nanowells. In some embodiments, the presence or quantity of at least three different Aβ peptides is detected, and an effective amount of a therapeutic compound is administrated to treat Alzheimer in a subject in need thereof.
Resumen de: EP4548992A2
Provided are methods for the detection or quantitation of amyloid beta. In a particular aspect, provided herein are methods for detecting amyloid beta or fragments thereof by mass spectrometry. In another aspect, provided herein are methods for determining the ratio of amyloid beta 42 (Aβ42) to amyloid beta 40 (Aβ40). In another aspect, provided herein are methods for diagnosis or prognosis of Alzheimer's disease or dementia.
Resumen de: EP4549585A1
A kit for diagnosing Alzheimer's disease and a pharmaceutical composition for treating Alzheimer's disease are disclosed, in which EDIL3 or a nucleic acid encoding EDIL3 is used as an index or target.
Resumen de: AU2023357033A1
The present disclosure generally relates to the surprising discovery that subjects likely to respond to treatment with an 11β-HSD1 inhibitor can be selected for treatment based on a comparison between a baseline level of a tau protein in the subject, and a reference level of the tau protein.
Nº publicación: WO2025090763A1 01/05/2025
Solicitante:
SIEMENS HEALTHCARE DIAGNOSTICS INC [US]
SIEMENS HEALTHCARE DIAGNOSTICS INC
Resumen de: WO2025090763A1
Methods, kits and compositions of detecting analytes, typically analytes relevant to neurodegenerative diseases such as neurofilament light chain, in a sample are described herein using chemiluminescent labels. Solid supports, reagents, and compounds for use in these methods are also described. Typically, the methods involve specific assay formats which provide the requisite high resolution for detecting low concentrations of analytes in samples and may be used in positions of the healthcare ecosystem close to the patient. These methods, systems, and apparatuses may afford early detection and prognosis of a wide variety of neurodegenerative diseases such as Alzheimer's disease and multiple sclerosis.
BOPI
Sede Electrónica
